Topical treatments for scalp psoriasis

Drugs

Volumn 68, Issue 16, 2008, Pages 2293-2302

  Warren, Richard B ^a   Brown, Benjamin C ^a   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Betamethasone valerate, therapeutic use; Calcipotriol, therapeutic use; Clobetasol, therapeutic use; Dithranol, therapeutic use; Fluocinolone acetonide, therapeutic use; Psoriasis, treatment; Tacalcitol, therapeutic use; Topical

Indexed keywords

ANTIFUNGAL AGENT; ANTIPSORIASIS AGENT; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; BIFONAZOLE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID DERIVATIVE; DITHRANOL; FALECALCITRIOL; FLUOCINOLONE ACETONIDE; KERATOLYTIC AGENT; MOMETASONE FUROATE; PLACEBO; PSORALEN; PYRITHIONE ZINC; SALICYLIC ACID; TACALCITOL; TAR; UNCLASSIFIED DRUG; UNGUENTUM COCOIS; UREA; VITAMIN D DERIVATIVE;

ATROPHY; CLINICAL FEATURE; CLINICAL TRIAL; CREAM; DANDRUFF; DIFFERENTIAL DIAGNOSIS; DOSAGE SCHEDULE COMPARISON; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG TOLERABILITY; ERYTHEMA; HUMAN; HYPERPIGMENTATION; LOTION; MONOTHERAPY; OINTMENT; PATIENT COMPLIANCE; PHOTOTHERAPY; PREVALENCE; PSORIASIS; PSYCHOSOCIAL DISORDER; PUVA; REVIEW; SCALP; SEBORRHEIC DERMATITIS; SKIN IRRITATION; TREATMENT PLANNING; ULTRAVIOLET B RADIATION;

EID: 55049092549     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868160-00003     Document Type: Review

References (64)

1. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71
2. Van de Kerkhof PC, Franssen ME. Psoriasis of the scalp: diagnosis and management. Am J Clin Dermatol 2001; 2: 159-65
3. Van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998; 197: 326-34
4. Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol 2002; 138: 803-7
5. Schoorl WJ, van Baar HJ, Van de Kerkhof PC. The hair root pattern in psoriasis of the scalp. Acta Derm Venereol 1992; 72: 141-2
6. Bardazzi F, Fanti PA, Orlandi C, et al. Psoriatic scarring alopecia: observations in four patients. Int J Dermatol 1999; 38: 765-8
7. Van de Kerkhof PC, Chang A. Scarring alopecia and psoriasis. Br J Dermatol 1992; 126: 524-5
8. Kretzschmar L, Bonsmann G, Metze D, et al. Scarring psoriatic alopecia [in German]. Hautarzt 1995; 46: 154-7
9. Faergemann J, Bergbrant IM, Dohse M, et al. Seborrhoeic dermatitis and pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144: 549-56
10. Dawson Jr TL. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J Investig Dermatol Symp Proc 2007; 12: 15-9
11. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 1967; 48: 181-3
12. Zhai H, Fautz R, Fuchs A, et al. Human scalp irritation compared to that of the arm and back. Contact Dermatitis 2004; 51: 196-200
13. Maibach HI, Stoughton RB. Topical corticosteroids. Med Clin North Am 1973; 57: 1253-64
14. Engel DJ, Marx AF, Rekker RF, et al. Topically active corticosteroids: a quantitative evaluation of McKenzie's skin-blanching test. Arch Dermatol 1974; 109: 863-5
15. Hovding G. Treatment of psoriasis of the scalp with betamethasone 17, 21-dipropionate plus salicylic acid lotion ('Diprosalic'). Pharmatherapeutica 1981; 3: 61-6
16. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol 2005; 53: S39-49
17. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003; 4: 221-4
18. Jarratt M, Breneman D, Gottlieb AB, et al. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004; 3: 367-73
19. Griffiths CEM, Finlay AY, Fleming CJ, et al. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006; 17: 90-5
20. Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005; 16: 31-6
21. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628-32
22. Andreassi L, Giannetti A, Milani M. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003; 148: 134-8
23. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003; 7: 185-92
24. Franz TJ, Parsell DA, Myers JA, et al. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol 2000; 39: 535-8
25. Pauporte M, Maibach H, Lowe N, et al. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat 2004; 15: 360-4
26. Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 1990; 282: 164-7
27. Patel B, Siskin S, Krazmien R, et al. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998; 38: 1010-1
28. Kragballe K. Vitamin D3 analogues. Dermatol Clin 1995; 13: 835-9
29. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment: a review of its use in the management of psoriasis. Am J Clin Dermatol 2001; 2: 95-120
30. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130: 483-7
31. Duweb G, Alhaddar J, Abuhamida M. Calcipotriol solution in scalp psoriasis. Int J Tissue React 2005; 27: 163-6
32. Thaci D, Daiber W, Boehncke WH, et al. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001; 203: 153-6
33. Barnes L, Altmeyer P, Forstrom L, et al. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000; 10: 199-204
34. Duweb GA, Abuzariba O, Rahim M, et al. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000; 20 (3-4): 65-8
35. Ruzicka T, Trompke C. Treatment of scalp psoriasis: an effective and safe tacalcitol emulsion [in German]. Hautarzt 2004; 55: 165-70
36. Durakovic C, Malabanan A, Holick MF. Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study. Br J Dermatol 2001; 144: 500-6
37. Chen TC, Holick MF. Hexafluoro-1,25-dihydroxyvitamin D3 has markedly increased potency in inhibiting proliferation of cultured human keratinocytes compared with 1,25-dihydroxyvitamin D3. Br J Dermatol 2000; 143: 72-8
38. Downs AM. Dovobet ointment under occlusion overnight for troublesome scalp psoriasis. Acta Derm Venereol 2006; 86: 57-8
39. Cassano N, Vena GA. Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product. Acta Derm Venereol 2007; 87: 85-6
40. Papp K, Berth-Jones J, Kragballe K, et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol 2007; 21: 1151-60
41. Bashir SJ, Dreher F, Chew AL, et al. Cutaneous bioassay of salicylic acid as a keratolytic. Int J Pharm 2005; 292: 187-94
42. Going SM, Guyer BM, Jarvie DR, et al. Salicylic acid gel for scalp psoriasis. Clin Exp Dermatol 1986; 11: 260-2
43. Griffiths CEM, Clark CM, Chalmers RJG, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1-125
44. Arnold WP. Tar. Clin Dermatol 1997; 15: 739-44
45. Langner A, Wolska H, Hebborn P. Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis 1983; 32: 290-6
46. Wheeler LA, Saperstein MD, Lowe NJ. Mutagenicity of urine from psoriatic patients undergoing treatment with coal tar and ultraviolet light. J Invest Dermatol 1981; 77: 181-5
47. Yuspa SH. Cutaneous chemical carcinogenesis. J Am Acad Dermatol 1986; 15: 1031-44
48. McGill A, Frank A, Emmett N, et al. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J 2005; 19: 1012-4
49. Wulff-Woesten A, Ohlendorf D, Henz BM, et al. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol 2004; 17: 91-7
50. Shemer A, Nathansohn N, Kaplan B, et al. Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol 2000; 39: 532-4
51. Bailey P, Arrowsmith C, Darling K, et al. A double-blind randomized vehicle-controlled clinical trial investigating the effect of ZnPTO dose on the scalp vs antidandruff efficacy and antimycotic activity. Int J Cosmet Sci 2003; 25: 183-8
52. Quadri G, Cavallero W, Milani M. Efficacy of a new antidandruff thermophobic foam: a randomized, controlled, investigator-blinded trial vs ketoconazole 2% scalp fluid. J Cosmet Dermatol 2005; 4: 23-6
53. Saple DG, Ravichandran G, Desai A. Evaluation of safety and efficacy of ketoconazole 2% and zinc pyrithione 1% shampoo in patients with moderate to severe dandruff: a postmarketing study. J Indian Med Assoc 2000; 98: 810-1
54. Sawleshwarkar SN, Salgaonkar V, Oberai C. Multicenter, open-label, non-comparative study of a combination of polytar and zinc pyrithione shampoo in the management of dandruff. Indian J Dermatol Venereol Leprol 2004; 70: 25-8
55. Pierard-Franchimont C, Goffin V, Decroix J, et al. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol 2002; 15: 434-41
56. Rowlands CG, Danby FW. Histopathology of psoriasis treated with zinc pyrithione. Am J Dermatopathol 2000; 22: 272-6
57. Taneja A, Racette A, Gourgouliatos Z, et al. Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study. Int J Dermatol 2004; 43: 462-7
58. Caccialanza M, Piccinno R, Cappio F, et al. Phototherapy of psoriasis of the scalp: results in 21 patients treated with a special portable ultraviolet rays lamp [in Italian]. G Ital Dermatol Venereol 1989; 124: LXI-V
59. Taylor CR, Racette AL. A 308-nm excimer laser for the treatment of scalp psoriasis. Lasers Surg Med 2004; 34: 136-40
60. Braun R, Dotterud LK, Falk ES. Comparison of betamethasone valerate solution with phototherapy (UVB comb) in scalp psoriasis treatment [letter]. Acta Derm Venereol 1998; 78: 385
61. Halpern SM, Anstey AV, Dawe RS, et al. Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group. Br J Dermatol 2000; 142: 22-31
62. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002; 146: 351-64
63. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005; 53: S59-69
64. van der Vleuten CJM, Van de Kerkhof PCM. Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs 2001; 61: 1593-8